Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Vertex Pharmaceuticals” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 159
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 159 pipeline programs matching "Vertex Pharmaceuticals" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

159 results for “Vertex Pharmaceuticals” Back to intelligence hub

Search results

Page 7 of 7
  1. VX-840

    Vertex Pharmaceuticals (Australia) Pty.

    APOL1-mediated Kidney Disease

    phase 1 small molecule completed

    1 trial
  2. VX-973

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    2 trials
  3. VX-985 or matching placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial
  4. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    phase 1 small molecule completed

    6 trials
  5. Vanzacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 1 small molecule completed

    1 trial
  6. lumacaftor 200 mg q12h + ivacaftor 250 mg q12h

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial
  7. telaprevir (VX-950)

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatic Insufficiency

    phase 1 small molecule completed

    1 trial
  8. telaprevir formulation A

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 1 small molecule completed

    1 trial
  9. LUM/IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    approved small molecule completed

    8 trials
  10. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Acute Pain

    approved small molecule completed

    2 trials
  11. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Pain

    approved small molecule active

    6 trials
  12. Telaprevir

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    approved small molecule completed

    11 trials
  13. suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Pain, Acute Postoperative

    approved small molecule active

    1 trial
  14. AVN944

    Vertex Pharmaceuticals (Australia) Pty.

    Refractory Solid Tumors

    small molecule terminated

    1 trial
  15. Standard OGTT

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    other completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.